Preclinical SCI Data Shows Encouraging Neuroprotection
SCI
Phase II TBI Program Ongoing
Military Interest in Oxycyte Growing
Read the full analyst report on "OXBT"
Zacks Investment Research
On June 3, 2010,
Oxygen Biotherapeutics (
OXBT) reported that two preclinical studies demonstrated Oxycyte delivered marked neuroprotective effects in a rat model of spinal cord injury. The data show histologically, Oxycyte improved the volume of preserved neuronal tissue in the spinal cord following injury.
SCI
) in the Rat" were presented in September 2009 at the annual National-International Neurotrauma Symposium by Dr. Ross Bullock, University of Miami Miller School of Medicine. Both studies received funding from Oxygen Biotherapeutics.
This is encouraging preclinical data and allows management to move closer toward filing an investigation new drug (
INDPhase II TBI Program Ongoing
The company’s phase IIb traumatic brain injury (
TBI
The dose escalation study will focus on finding the lowest dose of Oxycyte that provides clinical benefit in traumatic brain injury while minimizing adverse effects. Dose levels of Oxycyte will start at 1.0 ml/kg body weight and escalate in steps to 2.0 ml/kg, and 3.0 ml/kg for subsequent cohorts. Escalation will only occur after a favorable review of safety data by an independent Data Safety Monitoring Board (DSMB).
In May 2010, management held an investigator meeting with all participating sites. No results have yet been reported, but we anticipate an update from the first cohort perhaps later this year. The second (45-50 people) and third (35-40 people) cohorts are on track to begin enrolling following the interim analysis of the first cohort. Full data is expected in 18 months.
Early-stage clinical work conducted by Oxygen Biotherapeutics demonstrates that 40% to 70% of damaged brain tissue can be saved by Oxycyte post TBI. Preclinical animal studies demonstrated that rats treated with Oxycyte following a lateral fluid percussion injury (LFPI) had statistically superior scores (lower times to complete) on Morris water maze tests than rats receiving saline solution only.
Military Interest in Oxycyte Growing
Another major cause of TBI is Military Blast Injury (
MBI). There were an estimated 380k such incidences among American military personnel from 2002-2008. TBI is the largest killer in the War on Terror, and primarily occurs due to roadside blasts or bombs. Time to treatment is a significant hurdle to reducing the severity of TBI-MBI on the battlefield. Roughly 50% of military severe TBI survivors suffer major long-term impairments.
The ideal medication would be to rapidly provide oxygen rich fluid to the damaged tissue. It must be portable, stable at room temperature, and easy to use quickly after a TBI-MBI occurs. That’s Oxycyte! As such, we expect significant U.S. military interest in Oxycyte should the STOP-TBI program offer positive data.
We note the U.S. Navy is also looking at Oxycyte for the potential treatment of decompression sickness. An IND for this indication is expected later in 2010. Approval for use of Oxycyte by the U.S. Navy based on animal-rule data could come by 2012. This could be a significant opportunity for Oxygen Bio based on the characteristics of the drug and the potential for broad-scale deployment on U.S. or NATO submarines.
In a bullish scenario, we envision the U.S. Navy purchasing Oxycyte for its 250 – 300 submarines with an estimated 100 to 120 doses per ship. The same characteristics that make Oxycyte attractive to the U.S. Army -- portable, stable at room temp, easy to use -- also fit well within what the U.S. Navy would be looking for on a disabled vessel.
Read the full analyst report on "OXBT"
Zacks Investment Research
© 2026 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
To add Benzinga News as your preferred source on Google, click here.
